ARTICLE | Company News
PanGenetics, Bioceros deal
March 2, 2015 8:00 AM UTC
PanGenetics granted Bioceros exclusive, worldwide rights to develop preclinical mAb agonists of CD40 to treat cancer. PanGenetics will receive an upfront payment and is eligible for undisclosed miles...